Incyte announced Monday an agreement to acquire Vega Therapeutics, a wholly-owned subsidiary of Star Therapeutics, for up to $2 billion, confirming rumours first reported by the Financial Times a day earlier. The deal — which includes $1.25 billion upfront — is focused on the investigational monoclonal antibody VGA039 for von Willebrand disease (VWD). "VGA039 fits directly into our strategy of building a top-tier growth company for the future," said Incyte CEO Bill Meury, who took up the reins

Transaction will add FDA Breakthrough Device-Designated technology with active U.S. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs. Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and Israel. Galmed contemplates an investment of $6 million to launch Colospan's device during H2 2026 in Europe with an initial focus on Germany, Austria and Switzerl

June 2, 2026 -- Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv"), a liquid biopsy company focused on innovative diagnostics for cancer, and Neovia Oncology LLC, a Delaware based pharmaceutical company dedicated to developing novel oncology therapies, announced the signing of a strategic partnership agreement to collaborate on Neovia's upcoming studies treating patients with advanced multiple drug resistant solid tumors who are entering late lines of therapy. The collaboration is expe

June 2, 2026 -- SMi Systems announces today the execution of a non-exclusive evaluation collaboration with Luminex Corporation to assess the feasibility of using Luminex beads with SMi's single-molecule imaging platform and to compare SMi's analytical sensitivity with Luminex's current xMAP readers under defined test conditions. The evaluation is initially focused on research activities to validate the potential for SMi's technology to complement Luminex's industry leading xMAP technology. SMi

Servier has agreed to acquire Edgewise Therapeutics' muscular dystrophy business for up to $2.65 billion, gaining control of the latter's late-stage candidate sevasemten. The move comes on the heels of the French drugmaker's roughly $2.5-billion takeout of Day One Biopharmaceuticals earlier this year. Monday's transaction includes $1.55 billion in upfront cash and as much as $1.1 billion in regulatory and commercial milestones. Expected to close in the third quarter, the deal transfers to Servi

Expanding in the metabolic space, Eli Lilly has struck a back-loaded licensing deal with South Korea’s Hanmi Pharm for a mid-stage GLP-2 agonist being trialed for short bowel syndrome. Eli Lilly’s late-spring dealmaking spree shows no sign of stopping as the pharma giant stuck a licensing agreement with South Korean biotech Hanmi Pharm worth up to $1.2 billion for access to a potential next wave of metabolic drugs. Under the deal, Lilly will help develop Hanmi’s Phase 2 GLP-2 agonist sonefpegl

Pfizer continues its dealmaking spree by striking a back-heavy partnership with China’s Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer. Pfizer is teaming up with China’s Innovent Biologics to advance a broad pipeline of cancer therapies, continuing the New York pharma’s recent dealmaking spree. Under the terms of the agreement, announced late on Thursday, Pfizer will make a $650 million upfront payment and offer up to $9.85 billion in development, regulatory a

Repeat medtech founder and operator behind multiple nine-figure exits launches investment and strategic advisory platform to help founders build, fund and scale medical device companies May 28, 2026 -- John Slump, co-founder and former president and CEO of Atraverse Medical, announced the launch of Metis MedTech, an investment and strategic advisory platform for medical device founders. The launch follows the close of Johnson & Johnson's acquisition of Atraverse Medical on May 15, 2026, which s

Collaboration integrates AI discovery, human brain organoid modeling, and in vivo validation to generate differentiated neurology assets for pharmaceutical partnering and development May 28, 2026 -- Lunai Bioworks' (NASDAQ: LNAI) wholly owned subsidiary BioSymetrics and BrainStorm Therapeutics today announced a strategic collaboration and Letter of Intent (LOI) to jointly discover, validate, and advance novel therapeutic targets for neurological diseases. The collaboration is supported by a new

Strategic partnership combines NorthStar's commercial-scale radioisotope production capabilities with QSA Global's expertise in lifecycle management of Radium-226 (Ra-226), the starting material for Ac-225 production Agreement aims to strengthen NorthStar's no carrier added (n.c.a) Ac-225 supply chain by establishing a reliable, closed-loop source of high-purity Ra-226 target materials May 27, 2026 -- QSA Global, Inc., a global leader in specialized radioactive source manufacturing and medical